Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$7.36
-$0.03(-0.21%)
At close: 4:00 PM EST
$7.36
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.37 - $11.30
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$130.29M
Enterprise Value$236.42
Total Cash (Recent Filing)$72.30M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 04, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside42.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$65.33M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginSustained, large top-line growth paired with an ~86% gross margin shows strong product-level economics and scalable unit profitability. Durable high margins give the company structural leverage to drive future operating margin improvement as commercial volumes expand and manufacturing efficiency continues.
Reimbursement: Category I CPTEarning a Category I CPT code is a structural reimbursement milestone that reduces billing ambiguity and supports hospital adoption. Over time, clearer coding and improving Medicare Advantage approval rates should lower access friction and sustain procedure-level revenue growth for Barostim.
BENEFIT‑HF Trial Potential TAMA successful BENEFIT‑HF program could materially enlarge the long‑term addressable market, potentially tripling TAM to ~$30B. This structural clinical opportunity underpins multi‑year growth optionality and justifies continued commercial investment if trial outcomes support broader label adoption.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow erodes runway and forces external funding or cost reduction. Over the medium term this constrains strategic flexibility, raises dilution or debt risk, and may limit the company’s ability to scale commercial operations without incremental financing.
Rising Leverage & Thin EquityMaterial increase in leverage and a much smaller equity cushion reduce financial flexibility and heighten refinancing and covenant risks. Higher interest costs and limited capital buffers can restrict investments, increase cash burn pressure, and amplify downside in adverse commercial scenarios.
Long Timeline To Realize Trial UpsideThe major TAM expansion depends on a multi‑year trial and follow‑up, meaning meaningful regulatory-driven revenue upside is distant. That protracted timeline forces reliance on current commercialization to fund operations and increases execution and financing risk over the intermediate term.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.37 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $130.29M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Aug 04, 2026 which is in 15 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.504 by $0.004.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.53.
How many shares outstanding does CVRx have?
CVRx has 26,535,944 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.504. Following the earnings report the stock price went down -23.844%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (42.66% Upside)
$10.50 (42.66% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 207.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-120.77%
Trailing 12-Months
Asset Growth
-23.04%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(42.66% Upside)
Technical Analysis
Ownership Overview
29.03% Insiders
6.20% Mutual Funds
31.86% Other Institutional Investors
26.40% Public Companies and
Individual Investors